Citi resumes Bureau Veritas coverage with neutral rating

Published 07/02/2025, 09:50
Citi resumes Bureau Veritas coverage with neutral rating

Friday, Citi analysts resumed coverage of Bureau Veritas SA (BVI:FP) (OTC: BVRDF), assigning a Neutral rating to the stock and setting a price target of EUR30.80. The company, currently valued at $13.7 billion, trades at a P/E ratio of 26.3x. The resumption follows a period during which the firm had suspended its rating on the company. The analysts have maintained their forecasts and target price from their most recent update in the "Bureau Veritas (BVI.PA) Model Update."

In the statement released today, the analysts noted their expectations for Bureau Veritas’ adjusted EBIT in 2025 to reach EUR1,055 million. They are modeling organic growth rates of 6.6% for 2025 and 5.9% for 2026, rates which they note are significantly higher than the historical norms observed before the COVID-19 pandemic. According to InvestingPro data, the company maintains a moderate debt level and has demonstrated consistent profitability, with a solid financial health score of "GOOD." However, they believe that these projections are in line with the current consensus expectations for the company.

The analysts did not alter their previous forecasts or target price, indicating a steady outlook for the company’s financial performance. Bureau Veritas, a global leader in testing, inspection, and certification services, has navigated the challenges posed by the pandemic and is now positioned for growth above historical trends, according to Citi’s analysis. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading slightly above its intrinsic value. Investors should note that the company’s next earnings report is scheduled for February 25, 2025, which could be a significant catalyst for the stock.

Citi’s neutral stance suggests that while they see potential in Bureau Veritas’ growth prospects, they also recognize that the current consensus has already accounted for this potential. The price target of EUR30.80 remains unchanged, providing investors with a benchmark for evaluating the stock’s performance as the company progresses towards its projected growth. InvestingPro subscribers have access to over 30 additional financial metrics and insights about Bureau Veritas, including detailed valuation analysis and growth projections.

As the market digests this latest input from Citi, Bureau Veritas shares will continue to be observed for their performance against the backdrop of the firm’s financial forecasts and the broader industry context. The stock has shown relatively low price volatility, with a beta of 0.88, making it an interesting consideration for stability-focused investors.

In other recent news, Bureau Veritas SA has been the subject of notable analyst attention. Bernstein maintained an Outperform rating on the company, keeping their price target steady at EUR36.00. The firm projects a robust fourth-quarter organic growth of 9.3% for Bureau Veritas, expecting the full-year margins to increase by 20 basis points to reach 16.1%. These projections align with the consensus estimates for the fiscal year 2024 earnings per share (EPS) and are slightly ahead by 1% for fiscal year 2025.

Bernstein highlighted the strong long-term growth drivers present across much of Bureau Veritas’s portfolio, as well as the positive momentum in margins. The firm’s EPS estimates for fiscal years 2025 and 2026 are 1%-2% above the market consensus, reflecting an optimistic view on the company’s financial performance. Bureau Veritas’s full-year 2024 results are expected to be announced soon, which investors and stakeholders eagerly anticipate to gauge the company’s trajectory and validate the analyst’s forecasts.

The Outperform rating by Bernstein suggests that Bureau Veritas shares are projected to outperform the overall market or sector average over the next 12 months. This rating underscores the confidence in Bureau Veritas’s ability to achieve forecasted growth and margin improvements. These recent developments indicate a positive outlook for Bureau Veritas, as per the analysis by Bernstein.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.